[177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy

International Journal of Cancer

Volumn 92, Issue 5, 2001, Pages 628-633

  De Jong, Marion ^a   Breeman, Wout A P ^a   Bernard, Bert F ^b   Bakker, Willem H ^a   Schaar, Michael ^b   Van Gameren, Arthur ^b   Bugaj, Joe E ^a   Erion, Jack ^a   Schmidt, Michelle ^b   Srinivasan, Ananth ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MALLINCKRODT PHARMACEUTICALS   (United States)

Author keywords

177Lu; Octreotate; Radionucleitide therapy; Receptor; Tumour

Indexed keywords

DEXTRO LYSINE; LANTHANIDE; LUTETIUM; OCTREOTATE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODECANE 1,4,7,10 TETRAACETIC ACID LUTETIUM 11]; OCTREOTIDE; RADIOISOTOPE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; YTTERBIUM; 3 TYR OCTREOTIDE; 3-TYR-OCTREOTIDE; CHELATING AGENT; DRUG DERIVATIVE;

ADRENAL TUMOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUGER ELECTRON SPECTROSCOPY; CONTROLLED STUDY; HYPOPHYSIS TUMOR; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; MALE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SCINTIGRAPHY; ANIMAL; AUTORADIOGRAPHY; KIDNEY; LEWIS RAT; METABOLISM; MORTALITY; RADIATION DOSE; SURVIVAL RATE; TISSUE DISTRIBUTION;

ANIMALS; AUTORADIOGRAPHY; CHELATING AGENTS; KIDNEY; LUTETIUM; MALE; OCTREOTIDE; PANCREATIC NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY DOSAGE; RATS; RATS, INBRED LEW; RECEPTORS, SOMATOSTATIN; SURVIVAL RATE; TISSUE DISTRIBUTION;

EID: 0035354343     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20010601)92:5<628::AID-IJC1244>3.0.CO;2-L     Document Type: Article

References (21)

1. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
2. Somatostatin receptor scintigraphy with [111InDTPA-D-Phe 1]- and [123I- Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients
3. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy
4. Therapy of neuroendocrine tumors with radiolabeled somatostatin- analogues
5. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver
6. Yttrium-90 DOTATOC: First clinical results
7. Yttrium-90-labelled somatostatin-analogue for cancer treatment
8. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phel-Tyr3- Octreotide: Preliminary report in cancer patients
9. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-D-Phel, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours
10. Targeted radiotherapy with 90Y-SMT487 (OctreoTher): A phase I study
11. High radiotherapeutic efficacy of [Lu-177]-DOTA-Y3-octreotate in a rat tumor model
12. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy
13. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor- targeted scintigraphy and radionuclide therapy
14. Absorbed fractions for electrons and beta particles in spheres of various sizes
15. Response to radionuclide therapy using 90Y- and 111In-labeled somatostatin analogs is dependent on tumor size
16. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake
17. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo
18. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats
19. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model
20. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer
21. Affinity profiles for human somatostatin subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use